Company Filing History:
1 out of 321 
1 out of 4 Years Active: 2014
Title: Jin Mi Oh - Innovator in Autoimmune Disease Treatment
Introduction
Jin Mi Oh is a prominent inventor based in Gyeonggi-do, South Korea. She has made significant contributions to the field of biotechnology, particularly in the treatment of autoimmune diseases. Her innovative work has led to the development of a unique therapeutic approach that targets key inflammatory pathways.
Latest Patents
Jin Mi Oh holds a patent for a groundbreaking invention titled "TNF-A and TWEAK dual antagonist for the prophylaxis and treatment of autoimmune diseases." This invention focuses on the TNFR2-TWEAKR fusion protein, which acts as a double-antagonist to TNF-α and TWEAK, both of which are major contributors to autoimmune arthritis. The composition comprising the TNFR2-TWEAKR fusion protein has shown remarkable efficacy in reducing the secretion of the inflammatory cytokine IL-17 while increasing the secretion of the anti-inflammatory cytokine IL-10 in Treg cells. This dual action is significantly more effective than using single proteins like TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein has demonstrated excellent treatment effects in a CIA mouse model and has potential applications in treating autoimmune rheumatoid arthritis by enhancing the expression of immune-suppressive Treg cells.
Career Highlights
Throughout her career, Jin Mi Oh has worked with esteemed organizations such as the Korea Research Institute of Bioscience and Biotechnology and the Industry-Academic Cooperation Foundation at the Catholic University of Korea. Her research has focused on innovative solutions for complex health issues, particularly in the realm of autoimmune diseases.
Collaborations
Jin Mi Oh has collaborated with notable colleagues, including Young Woo Park and Ki Won Jo. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic strategies.
Conclusion
Jin Mi Oh's contributions to the field of biotechnology, particularly through her patent on the TNFR2-TWEAKR fusion protein, highlight her role as an innovator in the treatment of autoimmune diseases. Her work not only advances scientific understanding but also offers hope for effective therapies in the future.